The Effect of Tang Forte (Royal Jelly) Capsule on Hypoglycemia and Clinical Course in COVID-19 Patients Under Corticosteroid Therapy.
Hamidreza PourfardAli AhmadiZahra HabibiMajid Asadi-SamaniNajmeh ShahinfardAkbar SoleimaniPublished in: Journal of evidence-based integrative medicine (2023)
Corticosteroids improve the complications of Covid-19 but may cause some side effects such as hyperglycemia. Royal jelly is one of the bee products that exert anti-inflammatory, insulin-like, and hypoglycemic activities. The present study was conducted to investigate the effect of royal jelly capsules on blood sugar and the clinical course of Covid-19 in the patients receiving corticosteroid therapy. In this clinical trial, 72 Covid-19 patients with positive reverse transcription polymerase chain reaction (RT-PCR) test and pulmonary involvement hospitalized in Shahrekord Hajar Hospital were enrolled and randomized into two groups: treatment (receiving corticosteroids and Royal Jelly 1000 mg capsules daily for 7 days) and placebo (given corticosteroids and placebo). Laboratory tests, blood sugar, and clinical courses were determined and compared. Data was analyzed using SPSS version 16. On day 7 after the onset of the intervention, the dosage and frequency of insulin, FBS level, and required corticosteroid showed a decrease in both groups but the inter-group difference was not significant ( P > .05). As well, the Spo2 level indicated a non-significant increase and hospital stay length indicated a non-significant decrease in the intervention group ( P > .05). Among the symptoms, only headache, cough, and dyspnea indicated an improvement in the intervention group ( P < .05). Overall, the results indicated the short-term consumption of royal jelly could not significantly improve blood sugar and the clinical course of Covid-19; however, it could significantly improve headache, cough, and dyspnea in the patients.
Keyphrases
- sars cov
- coronavirus disease
- umbilical cord
- double blind
- randomized controlled trial
- type diabetes
- clinical trial
- phase iii
- mesenchymal stem cells
- end stage renal disease
- healthcare
- respiratory syndrome coronavirus
- open label
- anti inflammatory
- pulmonary hypertension
- chronic kidney disease
- ejection fraction
- glycemic control
- peritoneal dialysis
- stem cells
- placebo controlled
- study protocol
- insulin resistance
- emergency department
- metabolic syndrome
- big data
- oxidative stress
- advanced cancer
- patient reported outcomes
- skeletal muscle
- machine learning
- smoking cessation
- palliative care